What Paracetamol/Codeïnefosfaat CF Treats: Main Uses and Benefits

This medicine is relevant for easing symptoms related to physical discomfort that is not sufficiently managed by non-opioid options. This combination is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate. It is applied in clinical settings that involve acute or unstable symptom patterns, such as post-operative recovery, pain from traumatic injuries, and flares of musculoskeletal discomfort.

---

Quick Fact: Support for Pronounced Discomfort

The combination is used when pain reaches a moderate to severe intensity, creating noticeable physiological strain that interferes with daily functioning.

---

This medicine is commonly used to help with symptoms that reach this high level of intensity, addressing symptoms that create noticeable physiological strain. The medicine is also relevant for managing symptoms related to systemic imbalance, such as fever. It supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

“This medication is commonly applied when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.”

Regulatory References

1. European Medicines Agency's safety review

Paracetamol/Codeïnefosfaat CF eligibility is strictly defined by regulatory bodies due to potential risks associated with the Codeine component.

Contraindicated Populations

Use of the medicine is absolutely prohibited for children under 12 years of age and for all adolescents under 18 years following tonsillectomy or adenoidectomy for sleep apnea. Use is also contraindicated in women who are breastfeeding and in patients identified as CYP2D6 ultra-rapid metabolizers of codeine. Further absolute prohibitions apply to individuals with significant respiratory depression, severe hepatic insufficiency, or known gastrointestinal obstruction.

Restricted and Conditional Use

The medicine is restricted or requires special caution in several populations. This includes elderly or debilitated patients, as well as those with severely impaired renal or liver function. Adolescents aged 12 to 18 years who have co-existing conditions that increase the risk of breathing difficulties (such as severe lung disease or obesity) are strongly advised against using this product. Permitted use is generally established for adults and adolescents 12 and older who meet all safety criteria.

Interactions with other medicines and products

Co-administration of Paracetamol/Codeïnefosfaat CF with other medicines requires careful consideration due to the risk of altering drug effects or increasing toxicity, as documented in regulatory information.

Clinically Significant Interactions

Interacting Substance/Class	Potential Resulting Interaction
Central Nervous System (CNS) Depressants (e.g., sedatives, hypnotics, general anesthetics, alcohol)	Increased risk of profound sedation, respiratory depression, coma, and death due to additive depressant effects.
CYP2D6 Inhibitors (e.g., quinidine, paroxetine)	Decreased formation of the active metabolite (morphine) from codeine, potentially leading to reduced effectiveness.
Anticoagulants (e.g., warfarin)	Increased anticoagulant effect and risk of bleeding with prolonged use of the paracetamol component, requiring INR monitoring.
Serotonergic Drugs (e.g., SSRIs, triptans)	Increased risk of serotonin syndrome.

Absorption Modifiers and Contraindications

Substances that affect gastric motility, such as metoclopramide (increases absorption rate) or propantheline (decreases absorption rate), can alter paracetamol plasma concentrations. Colestyramine reduces paracetamol absorption and should not be given within one hour of dosing. Co-administration is contraindicated with other products containing paracetamol or with mixed opioid agonist/antagonists (e.g., nalbuphine) to avoid maximum dose exceedance and precipitated withdrawal, respectively.

Population Note: Use is restricted in individuals identified as CYP2D6 ultra-rapid metabolizers due to the high risk of opioid toxicity from rapid codeine-to-morphine conversion.

The product combines two agents, Paracetamol and Codeine, which act on distinct physiological systems to modulate nociceptive input and thermoregulation.

Paracetamol's mechanism primarily involves the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2, in the central nervous system (CNS). This inhibition leads to a reduced synthesis of prostaglandins (PGs), which mediate pain signaling and fever. This action modulates the nociceptive signaling pathway and suppresses pyrogen production in the hypothalamic thermoregulatory center. Due to its localized CNS effect, peripheral anti-inflammatory activity is not significant.

Codeine acts as a pro-drug, being metabolized by the cytochrome P450 enzyme CYP2D6 to morphine, its active metabolite. Morphine then functions as an agonist at mu-opioid receptors (MOR) in the CNS, inhibiting neuronal signaling in ascending and descending nociceptive pathways. This binding modulates pain transmission and modifies affective components of nociception. The combined pharmacological action results in simultaneous modulation of these processes.

This section details the administration guidelines for Paracetamol/Codeïnefosfaat CF. All instructions are for oral administration of the tablets.

Official Dosing and Frequency

The dosage must adhere to strict frequency and maximum limits to ensure correct use:

• Adults (and Adolescents over 16 years): The standard dose is two tablets per intake. This dose should not be repeated more frequently than every four to six hours. The absolute maximum is eight tablets within any 24-hour period.
• Children and Adolescents (12 to 15 years): The recommended dose is one tablet per intake, not to exceed four doses (four tablets) in 24 hours. The dose must be separated by a minimum interval of six hours.
• Children under 12 years: This medicine should not be used in children below the age of 12 years.

Administration Conditions

Adherence to the time constraints of treatment is mandatory. The ingestion of the tablets with food and drink does not affect the efficacy of the medicinal product.

• Maximum Duration of Use: Self-treatment with this medicine must be limited to 3 days. Use beyond this period requires consultation with a healthcare professional to avoid the risk of developing codeine dependence and to minimise the risk of medication-overuse headache.
• Preparation: The tablets should be taken whole, or the score line is only to facilitate breaking for ease of swallowing and is not intended to divide the tablet into equal halves for dosing.

In the event of a missed dose, the next administration must still respect the minimum four- to six-hour dosing interval.

Efficacy in Acute Pain Management

Research has explored the use of the combination of paracetamol (acetaminophen) and codeine phosphate in managing moderate to moderately severe acute pain, particularly in the post-operative setting. Multiple randomized controlled trials (RCTs) and systematic reviews have studied whether the addition of codeine to paracetamol affects pain intensity and the time until supplementary pain relief is required.

Studies suggest that combining paracetamol with codeine may provide additional pain relief compared to paracetamol alone, particularly at higher codeine doses (e.g., 60 mg per dose) used in research. For participants with moderate to severe post-operative pain, the combination was associated with a higher rate of achieving adequate pain relief within the first four to six hours after a single dose.

Pharmacokinetics and Genetic Factors

Codeine's analgesic action depends on its conversion to morphine by the liver enzyme CYP2D6. Genetic differences in the CYP2D6 enzyme can significantly affect this conversion, creating different metabolizer types, which were explored in research:

• Poor Metabolizers: Individuals in this group may convert little codeine into morphine, resulting in little or no pain relief from the medication.
• Ultra-rapid Metabolizers: These individuals convert codeine to morphine very quickly and efficiently. This can lead to unusually high and potentially dangerous levels of morphine in the blood, which carries an increased risk of serious adverse events like respiratory depression.

Safety Considerations

Evidence confirms that codeine carries an inherent risk of dependence and misuse, which is often cited in safety reviews. Furthermore, research findings prompted regulatory warnings regarding the use of codeine in children and in breastfeeding mothers who are ultra-rapid metabolizers, due to the risk of life-threatening respiratory depression in the infant.

Common questions about Paracetamol/Codeïnefosfaat CF (FAQ)

Q: How long does it usually take for Paracetamol/Codeïnefosfaat CF to start working?

A: Official information indicates that the active component of codeine, morphine, typically reaches its maximum concentration in the blood about 60 minutes after ingestion. This provides an estimate of when the active component reaches its highest level in the blood, which often correlates with the onset of the main pain-relieving action.

Q: Is it normal to feel a bit drowsy or 'foggy' after taking Paracetamol/Codeïnefosfaat CF?

A: Yes, regulatory documents list drowsiness, dizziness, and sedation as common adverse reactions. This feeling is a known, expected effect of the medicine, primarily due to the codeine component. If this effect is severe or causes concern, you may wish to consult with a healthcare professional.

Q: Can I combine Paracetamol/Codeïnefosfaat CF with ibuprofen for extra pain relief?

A: Official health guidance in certain regions suggests that it may be acceptable to take co-codamol with ibuprofen, as they work on different pathways. However, it is important to avoid taking any other products that also contain paracetamol while using this medicine to prevent exceeding the maximum recommended dose.

Q: Can people who are 'ultra-rapid metabolizers' of codeine use Paracetamol/Codeïnefosfaat CF safely?

A: Regulatory information states that use of this medicine is contraindicated (not permitted) in individuals identified as CYP2D6 ultra-rapid metabolizers. This is because their bodies quickly convert codeine into high and potentially dangerous levels of morphine, which significantly increases the risk of opioid toxicity.

Q: Is it safe to drive or operate machinery while taking Paracetamol/Codeïnefosfaat CF?

A: Official product information advises caution because this medicine can cause side effects like drowsiness and sedation. Because these effects can impair concentration, it is generally advised to avoid driving or operating machinery until you know how this medication affects you.

Q: Is it safe to take Paracetamol/Codeïnefosfaat CF if I have known heart problems?

A: Regulatory documents advise that caution is necessary for patients with a history of cardiac arrhythmias (irregular heartbeat) or other forms of impaired cardiac function. The decision to use this medicine must be made by a healthcare provider who can carefully consider the potential risks and benefits in the context of your condition.

Q: Can I take Paracetamol/Codeïnefosfaat CF if I also take anticoagulants?

A: Official drug labels warn that using this medicine while taking anticoagulants (like warfarin) may enhance the anticoagulant effect due to the paracetamol component. This increases the risk of bleeding. Close monitoring and potential adjustment of anticoagulant therapy may be required by a healthcare provider.

Q: What happens if I forget to take a scheduled dose of Paracetamol/Codeïnefosfaat CF?

A: If a dose is missed, regulatory guidance advises against taking two doses together. The next administration must still adhere to the minimum required time interval (e.g., four to six hours) before taking the subsequent dose.

Q: Can I take Paracetamol/Codeïnefosfaat CF if I have a history of kidney issues?

A: Official information advises that caution is necessary for patients with renal impairment (impaired kidney function), and a different dose or timing may be required. The medicine is generally avoided if there is severe kidney impairment.

Q: What should I do if my pain feels worse or I become more sensitive to pain while on this medication?

A: Studies show that in some patients on long-term opioid therapy, including codeine, a condition called hyperalgesia (increased pain sensitivity) may occur. If your pain worsens or you become more sensitive to pain, regulatory information advises consulting with a physician for evaluation.

Q: Can I use this medication if I have a history of head injury or high pressure in the head?

A: Regulatory data advises that use is cautioned against in patients with a history of head injury or raised intracranial pressure (high pressure in the head). The codeine component can potentially complicate the assessment and management of these conditions.

Q: Are there any warnings about taking this medicine if I have an enlarged prostate?

A: Yes. Regulatory documents state that caution is advised if you have prostatic hypertrophy (an enlarged prostate). This is a standard warning for opioid-containing medicines.

Q: Can this medication lead to symptoms of metabolic acidosis in rare cases?

A: Official product information lists metabolic acidosis (an imbalance of acid and base in the body) as a potential consequence of a severe paracetamol overdose. This is a serious condition that would require immediate medical attention.

Official Storage and Disposal Requirements

Storage and disposal of Paracetamol/Codeïnefosfaat CF must strictly follow official regulatory guidelines to maintain product quality and safety.

Storage Conditions

This medication must be stored at a temperature below 25 C or 30 C, depending on the specific formulation. It is required to keep the product in the original container to protect the tablets from light and moisture. Due to the presence of codeine, the medication must be stored in a safe, secure place and kept out of the sight and reach of children to prevent unauthorized access.

Disposal Instructions

Unused or expired Paracetamol/Codeïnefosfaat CF must not be disposed of via household waste or wastewater. Disposal must be performed in accordance with local requirements for pharmaceutical waste, often involving return to a pharmacy or an approved drug take-back program.